Enveric Biosciences, Inc. financial data

Symbol
ENVB on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 304% % -13%
Return On Assets -242% % -47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 596,978 shares -94%
Common Stock, Shares, Outstanding 518,296 shares -94%
Entity Public Float $4,900,000 USD -31%
Common Stock, Value, Issued $5,183 USD -94%
Weighted Average Number of Shares Outstanding, Basic 313,242 shares 548%
Weighted Average Number of Shares Outstanding, Diluted 313,242 shares 548%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $3,376,238 USD -6.8%
General and Administrative Expense $6,134,253 USD 26%
Operating Income (Loss) $9,754,351 USD -10%
Nonoperating Income (Expense) $302,814 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $9,725,263 USD 1.1%
Income Tax Expense (Benefit) $1,731 USD
Net Income (Loss) Attributable to Parent $9,732,462 USD 1.3%
Earnings Per Share, Basic 23 USD/shares 75%
Earnings Per Share, Diluted 23 USD/shares 75%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $4,165,540 USD -4%
Property, Plant and Equipment, Net $196,521 USD -47%
Intangible Assets, Net (Excluding Goodwill) $168,744 USD
Assets $4,362,061 USD -8.9%
Accounts Payable, Current $683,707 USD 19%
Accrued Liabilities, Current $222,178 USD -12%
Liabilities, Current $905,885 USD 8%
Accumulated Other Comprehensive Income (Loss), Net of Tax $580,945 USD -8.6%
Retained Earnings (Accumulated Deficit) $112,652,321 USD -9.5%
Stockholders' Equity Attributable to Parent $3,456,176 USD -13%
Liabilities and Equity $4,362,061 USD -8.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,391,582 USD 8%
Net Cash Provided by (Used in) Financing Activities $4,448,914 USD -33%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 518,296 shares -94%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,053,409 USD -50%
Deferred Tax Assets, Valuation Allowance $13,655,575 USD 6.4%
Depreciation $159,494 USD -6.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $11,291,858 USD -15%
Deferred Tax Assets, Operating Loss Carryforwards $12,010,882 USD 10%
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $116,684,259 USD 8.7%
Amortization of Intangible Assets $168,744 USD -0.01%
Share-based Payment Arrangement, Expense $965,224 USD -34%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%